Matthew Gall - Nov 3, 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role: Chief Financial Officer
Signature: /s/ Matthew Gall
Stock symbol: KLRS
Transactions as of: Nov 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 11/3/2025, 05:25 PM
Previous filing: Aug 29, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Gall Matthew	Chief Financial Officer	C/O KALARIS THERAPEUTICS, INC., 400 CONNELL DRIVE SUITE 5500, BERKELEY HEIGHTS	/s/ Matthew Gall	2025-11-03	0001816194

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KLRS	Stock Option (Right to Buy)	Award	$0	+235K		$0.00	235K	Nov 3, 2025	Common Stock	235K	$4.99	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option was granted on November 3, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on November 3, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.